tiprankstipranks
Advertisement
Advertisement

NBTX Stock Latest News

Nanobiotix Updates Share Capital and Voting Rights as of March 31, 2026
Company AnnouncementsNanobiotix Updates Share Capital and Voting Rights as of March 31, 2026
50m ago
6K
NBTX
Nanobiotix price target raised to $36 from $26 at Guggenheim
PremiumThe Fly
Nanobiotix price target raised to $36 from $26 at Guggenheim
5d ago
NBTX
Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile
PremiumRatings
Nanobiotix: Late-Stage NBTXR3 Pipeline and Partnerships Underpin Buy-Rated Risk-Reward Profile
6d ago
NBTX
Nanobiotix price target raised to $37 from $26 at Leerink
PremiumThe Fly
Nanobiotix price target raised to $37 from $26 at Leerink
6d ago
NBTX
Nanobiotix Extends Cash Runway to 2028 as JNJ-1900 Oncology Program Advances and 2025 Results Filed
PremiumCompany Announcements
Nanobiotix Extends Cash Runway to 2028 as JNJ-1900 Oncology Program Advances and 2025 Results Filed
7d ago
6K
NBTX
Robust Phase 2 CONVERGE Data for JNJ-1900 Underpin Buy Rating and €32 Price Target on Nanobiotix
PremiumRatingsRobust Phase 2 CONVERGE Data for JNJ-1900 Underpin Buy Rating and €32 Price Target on Nanobiotix
8d ago
NBTX
Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright
Premium
The Fly
Nanobiotix price target raised to EUR 32 from EUR 23 at H.C. Wainwright
8d ago
NBTX
Nanobiotix presents first data from CONVERGE study
Premium
The Fly
Nanobiotix presents first data from CONVERGE study
8d ago
JNJ
NBTX
Nanobiotix Reports First Positive Phase 2 Data for NBTXR3 in Inoperable Stage 3 Lung Cancer
PremiumCompany Announcements
Nanobiotix Reports First Positive Phase 2 Data for NBTXR3 in Inoperable Stage 3 Lung Cancer
8d ago
6K
NBTX
Nanobiotix Sets March 31 Release for Fourth-Quarter and Full-Year 2025 Results
PremiumCompany Announcements
Nanobiotix Sets March 31 Release for Fourth-Quarter and Full-Year 2025 Results
12d ago
6K
NBTX
Nanobiotix Denies Takeover Intentions Amid Media Speculation
PremiumCompany Announcements
Nanobiotix Denies Takeover Intentions Amid Media Speculation
13d ago
6K
NBTX
Nanobiotix says ‘no such intention’ for company to acquire control
PremiumThe Fly
Nanobiotix says ‘no such intention’ for company to acquire control
13d ago
NBTX
Nanobiotix Updates Share Capital and Voting Rights as of February 28, 2026
PremiumCompany AnnouncementsNanobiotix Updates Share Capital and Voting Rights as of February 28, 2026
26d ago
6K
NBTX
Nanobiotix Ramps Up Investor Outreach With March 2026 U.S. Conference Lineup
Premium
Company Announcements
Nanobiotix Ramps Up Investor Outreach With March 2026 U.S. Conference Lineup
1M ago
6K
NBTX
Nanobiotix initiated with a Buy at TD Cowen
Premium
The Fly
Nanobiotix initiated with a Buy at TD Cowen
2M ago
NBTX
Nanobiotix: Differentiated Radiotherapy Enhancer, J&J Partnership, and Multi-Indication Pipeline Undervalue Long-Term Upside, Supporting Buy Rating
PremiumRatings
Nanobiotix: Differentiated Radiotherapy Enhancer, J&J Partnership, and Multi-Indication Pipeline Undervalue Long-Term Upside, Supporting Buy Rating
2M ago
NBTX
Undervalued Royalty Stream and De‑Risked Partnership Economics Underpin Nanobiotix Buy Rating
PremiumRatings
Undervalued Royalty Stream and De‑Risked Partnership Economics Underpin Nanobiotix Buy Rating
3M ago
NBTX
Nanobiotix Announces Share Capital and Voting Rights Update as of November 30, 2025
PremiumCompany Announcements
Nanobiotix Announces Share Capital and Voting Rights Update as of November 30, 2025
4M ago
6K
NBTX
Nanobiotix Joins CAC Mid 60 and SBF 120 Indices
PremiumCompany Announcements
Nanobiotix Joins CAC Mid 60 and SBF 120 Indices
4M ago
6K
NBTX
Nanobiotix Discloses Managerial Transactions to Enhance Financial Flexibility
PremiumCompany AnnouncementsNanobiotix Discloses Managerial Transactions to Enhance Financial Flexibility
4M ago
6K
NBTX
Strategic Financial and Operational Advancements Propel Nanobiotix to a Buy Rating
Premium
Ratings
Strategic Financial and Operational Advancements Propel Nanobiotix to a Buy Rating
4M ago
NBTX
Nanobiotix Secures $71 Million Financing and Advances Cancer Treatment Programs
Premium
Company Announcements
Nanobiotix Secures $71 Million Financing and Advances Cancer Treatment Programs
4M ago
6K
NBTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >